{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T00:08:38Z","timestamp":1789085318275,"version":"build-2803163510"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T00:00:00Z","timestamp":1782345600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T00:00:00Z","timestamp":1789084800000},"content-version":"vor","delay-in-days":78,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Medical Research Fund of Yunnan University","award":["Key projects YDYXJJ2024- 0010"],"award-info":[{"award-number":["Key projects YDYXJJ2024- 0010"]}]},{"name":"Medical Research Fund of Yunnan University","award":["Key projects YDYXJJ2024- 0010"],"award-info":[{"award-number":["Key projects YDYXJJ2024- 0010"]}]},{"name":"Medical Research Fund of Yunnan University","award":["Key projects YDYXJJ2024- 0010"],"award-info":[{"award-number":["Key projects YDYXJJ2024- 0010"]}]},{"name":"Medical Research Fund of Yunnan University","award":["Key projects YDYXJJ2024- 0010"],"award-info":[{"award-number":["Key projects YDYXJJ2024- 0010"]}]},{"name":"Medical Research Fund of Yunnan University","award":["Key projects YDYXJJ2024- 0010"],"award-info":[{"award-number":["Key projects YDYXJJ2024- 0010"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Ophthalmol"],"DOI":"10.1186\/s12886-026-05030-1","type":"journal-article","created":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T14:55:10Z","timestamp":1782399310000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Early dynamic response on spectral-domain OCT predicts long-term visual outcome in diabetic macular edema treated with aflibercept"],"prefix":"10.1186","volume":"26","author":[{"given":"Aiping","family":"Deng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhe","family":"Gan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junyan","family":"Da","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiuyan","family":"Ning","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Run","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,25]]},"reference":[{"issue":"1","key":"5030_CR1","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s12886-018-1022-9","volume":"19","author":"V Castro-Navarro","year":"2019","unstructured":"Castro-Navarro V, Cervera-Taulet E, Navarro-Palop C, Monferrer-Adsuara C, Hernandez-Bel L, Montero-Hernandez J. Intravitreal dexamethasone implant Ozurdex(R) in naive and refractory patients with different subtypes of diabetic macular edema. BMC Ophthalmol. 2019;19(1):15.","journal-title":"BMC Ophthalmol"},{"issue":"1","key":"5030_CR2","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s40662-021-00237-3","volume":"8","author":"T Wang","year":"2021","unstructured":"Wang T, Zhang C, Xie H, Jiang M, Tian H, Lu L, et al. Anti-VEGF therapy prevents Muller intracellular edema by decreasing VEGF-A in diabetic retinopathy. Eye Vis (Lond). 2021;8(1):13.","journal-title":"Eye Vis (Lond)"},{"issue":"6","key":"5030_CR3","doi-asserted-by":"publisher","first-page":"382","DOI":"10.21037\/atm.2020.02.04","volume":"8","author":"Y Liu","year":"2020","unstructured":"Liu Y, Cheng J, Gao Y, Qin L, Min X, Zhang M. Efficacy of switching therapy to aflibercept for patients with persistent diabetic macular edema: a systematic review and meta-analysis. Ann Transl Med. 2020;8(6):382.","journal-title":"Ann Transl Med"},{"key":"5030_CR4","doi-asserted-by":"publisher","first-page":"781276","DOI":"10.3389\/fphar.2021.781276","volume":"12","author":"J Guo","year":"2021","unstructured":"Guo J, Zhou P, Liu Z, Dai F, Pan M, An G, et al. The Aflibercept-Induced MicroRNA Profile in the Vitreous of Proliferative Diabetic Retinopathy Patients Detected by Next-Generation Sequencing. Front Pharmacol. 2021;12:781276.","journal-title":"Front Pharmacol"},{"issue":"5","key":"5030_CR5","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1007\/s40123-024-00925-y","volume":"13","author":"G Panozzo","year":"2024","unstructured":"Panozzo G, Cicinelli MV, Dalla Mura G, Giannarelli D, Vadala M, Bonfiglio V, et al. Enhancing Diabetic Macular Edema Treatment Outcomes: Exploring the ESASO Classification and Structural OCT Biomarkers. Ophthalmol Ther. 2024;13(5):1383\u201398.","journal-title":"Ophthalmol Ther"},{"key":"5030_CR6","doi-asserted-by":"crossref","unstructured":"Marolo P, Borrelli E, Gelormini F, Boscia G, Parisi G, Fallico M, et al. Retinal thickness deviation: a new oct parameter for assessing diabetic macular edema. J Clin Med. 2023;12(12).","DOI":"10.3390\/jcm12123976"},{"issue":"4","key":"5030_CR7","doi-asserted-by":"publisher","first-page":"100478","DOI":"10.1016\/j.xops.2024.100478","volume":"4","author":"MT Massengill","year":"2024","unstructured":"Massengill MT, Cubillos S, Sheth N, Sethi A, Lim JI. Response of Diabetic Macular Edema to Anti-VEGF Medications Correlates with Improvement in Macular Vessel Architecture Measured with OCT Angiography. Ophthalmol Sci. 2024;4(4):100478.","journal-title":"Ophthalmol Sci"},{"issue":"4","key":"5030_CR8","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1177\/24741264221099429","volume":"6","author":"O Nanegrungsunk","year":"2022","unstructured":"Nanegrungsunk O, Gu SZ, Bressler SB, Du W, Amer F, Moini H, et al. Correlation of Change in Macular Thickness With Change in Visual Acuity in Diabetic Macular Edema: Post Hoc Analysis of VISTA and VIVID Trials. J Vitreoretin Dis. 2022;6(4):284\u20139.","journal-title":"J Vitreoretin Dis"},{"key":"5030_CR9","doi-asserted-by":"publisher","first-page":"1079217","DOI":"10.3389\/fendo.2022.1079217","volume":"13","author":"Z Yang","year":"2022","unstructured":"Yang Z, Tan TE, Shao Y, Wong TY, Li X. Classification of diabetic retinopathy: Past, present and future. Front Endocrinol (Lausanne). 2022;13:1079217.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"5030_CR10","doi-asserted-by":"publisher","first-page":"3033219","DOI":"10.1155\/2021\/3033219","volume":"2021","author":"N Dou","year":"2021","unstructured":"Dou N, Yu S, Tsui CK, Yang B, Lin J, Lu X, et al. Choroidal Vascularity Index as a Biomarker for Visual Response to Antivascular Endothelial Growth Factor Treatment in Diabetic Macular Edema. J Diabetes Res. 2021;2021:3033219.","journal-title":"J Diabetes Res"},{"issue":"3","key":"5030_CR11","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1007\/s10384-019-00657-8","volume":"63","author":"H Lee","year":"2019","unstructured":"Lee H, Kang KE, Chung H, Kim HC. Three-dimensional analysis of morphologic changes and visual outcomes in diabetic macular edema. Jpn J Ophthalmol. 2019;63(3):234\u201342.","journal-title":"Jpn J Ophthalmol"},{"key":"5030_CR12","first-page":"19","volume":"15","author":"S Li","year":"2025","unstructured":"Li S, Li M, Sun A, Zhang H. Hyperreflective Dots on SD-OCT: Implications for Predicting Treatment Outcomes in Diabetic Macular Edema. Diagnostics (Basel). 2025;15:19.","journal-title":"Diagnostics (Basel)"},{"key":"5030_CR13","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/s40662-018-0119-9","volume":"5","author":"A Campos","year":"2018","unstructured":"Campos A, Campos EJ, do Carmo A, Caramelo F, Martins J, Sousa JP, et al. Evaluation of markers of outcome in real-world treatment of diabetic macular edema. Eye Vis (Lond). 2018;5:27.","journal-title":"Eye Vis (Lond)"},{"key":"5030_CR14","doi-asserted-by":"publisher","first-page":"100916","DOI":"10.1016\/j.ajoc.2020.100916","volume":"20","author":"CK Chan","year":"2020","unstructured":"Chan CK, Sarraf D, Abraham P, Lalezary M, Lin SG, Chen X, et al. Meticulous multimodal analysis of aflibercept therapy for submacular vascularized pigment epithelial detachment associated with neovascular AMD in a prospective case series, the EVEN study. Am J Ophthalmol Case Rep. 2020;20:100916.","journal-title":"Am J Ophthalmol Case Rep"},{"issue":"1","key":"5030_CR15","doi-asserted-by":"publisher","first-page":"6816","DOI":"10.1038\/s41598-021-86348-2","volume":"11","author":"C Tuerksever","year":"2021","unstructured":"Tuerksever C, Pruente C, Hatz K. High frequency SD-OCT follow-up leading to up to biweekly intravitreal ranibizumab treatment in neovascular age-related macular degeneration. Sci Rep. 2021;11(1):6816.","journal-title":"Sci Rep"},{"issue":"9","key":"5030_CR16","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1001\/jamaophthalmol.2019.1963","volume":"137","author":"NM Bressler","year":"2019","unstructured":"Bressler NM, Odia I, Maguire M, Glassman AR, Jampol LM, MacCumber MW, et al. Association Between Change in Visual Acuity and Change in Central Subfield Thickness During Treatment of Diabetic Macular Edema in Participants Randomized to Aflibercept, Bevacizumab, or Ranibizumab: A Post Hoc Analysis of the Protocol T Randomized Clinical Trial. JAMA Ophthalmol. 2019;137(9):977\u201385.","journal-title":"JAMA Ophthalmol"},{"key":"5030_CR17","doi-asserted-by":"crossref","unstructured":"Kim YJ, Yeo JH, Son G, Kang H, Sung YS, Lee JY, et al. Efficacy of intravitreal AFlibercept injection For improvement of retinal nonperfusion in diabetic retinopathY (AFFINITY study). BMJ Open Diabetes Res Care. 2020;8(1).","DOI":"10.1136\/bmjdrc-2020-001616"},{"issue":"2","key":"5030_CR18","doi-asserted-by":"publisher","first-page":"149","DOI":"10.29271\/jcpsp.2020.02.149","volume":"30","author":"S Ozcaliskan","year":"2020","unstructured":"Ozcaliskan S, Balci S, Karasu B, Artunay O. Effect of Optical Coherence Tomography Patterns on One-year Outcomes of Aflibercept Therapy for Diabetic Macular Edema. J Coll Physicians Surg Pak. 2020;30(2):149\u201353.","journal-title":"J Coll Physicians Surg Pak"},{"issue":"1","key":"5030_CR19","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s40942-025-00777-z","volume":"12","author":"MP Rezende","year":"2025","unstructured":"Rezende MP, Faria FA, Beraldo DP, Polido J, Belfort R Jr., Cabral T. Analysis of correlations between biomarkers assessed with swept-source OCT and OCT angiography in naive patients with diabetic macular edema treated with aflibercept: a prospective study. Int J Retina Vitreous. 2025;12(1):18.","journal-title":"Int J Retina Vitreous"},{"issue":"7","key":"5030_CR20","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1038\/s41433-023-02886-1","volume":"38","author":"S Chandra","year":"2024","unstructured":"Chandra S, Gurudas S, Pearce I, McKibbin M, Kotagiri A, Menon G, et al. Baseline characteristics of eyes with early residual fluid post loading phase of aflibercept therapy in neovascular AMD: PRECISE study report 3. Eye (Lond). 2024;38(7):1301\u20137.","journal-title":"Eye (Lond)"},{"issue":"1","key":"5030_CR21","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1007\/s10792-025-03439-z","volume":"45","author":"Y Li","year":"2025","unstructured":"Li Y, Yu B, Si M, Yang M, Cui W, Zhou Y, et al. Enhancing diabetic retinopathy diagnosis: automatic segmentation of hyperreflective foci in OCT via deep learning. Int Ophthalmol. 2025;45(1):79.","journal-title":"Int Ophthalmol"},{"issue":"10","key":"5030_CR22","doi-asserted-by":"publisher","first-page":"1484","DOI":"10.1136\/bjo-2021-320897","volume":"107","author":"TYA Liu","year":"2023","unstructured":"Liu TYA, Ling C, Hahn L, Jones CK, Boon CJ, Singh MS. Prediction of visual impairment in retinitis pigmentosa using deep learning and multimodal fundus images. Br J Ophthalmol. 2023;107(10):1484\u20139.","journal-title":"Br J Ophthalmol"},{"issue":"1","key":"5030_CR23","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s40942-021-00284-x","volume":"7","author":"S Saxena","year":"2021","unstructured":"Saxena S, Akduman L, Meyer CH. External limiting membrane: retinal structural barrier in diabetic macular edema. Int J Retina Vitreous. 2021;7(1):16.","journal-title":"Int J Retina Vitreous"},{"issue":"1","key":"5030_CR24","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s40942-023-00473-w","volume":"9","author":"G Visioli","year":"2023","unstructured":"Visioli G, Alisi L, Mastrogiuseppe E, Albanese GM, Romano E, Iannetti L, et al. OCT biomarkers as predictors of visual improvement in diabetic macular edema eyes receiving dexamethasone implants. Int J Retina Vitreous. 2023;9(1):35.","journal-title":"Int J Retina Vitreous"},{"issue":"4","key":"5030_CR25","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1167\/tvst.10.4.7","volume":"10","author":"C Baumann","year":"2021","unstructured":"Baumann C, Iannetta D, Sultan Z, Pearce IA, Lohmann CP, Zheng Y, et al. Predictive Association of Pre-Operative Defect Areas in the Outer Retinal Layers With Visual Acuity in Macular Hole Surgery. Transl Vis Sci Technol. 2021;10(4):7.","journal-title":"Transl Vis Sci Technol"},{"key":"5030_CR26","doi-asserted-by":"crossref","unstructured":"Sen S, Ramasamy K, Sivaprasad S. Indicators of visual prognosis in diabetic macular oedema. J Pers Med. 2021;11(6).","DOI":"10.3390\/jpm11060449"},{"key":"5030_CR27","doi-asserted-by":"publisher","first-page":"100919","DOI":"10.1016\/j.preteyeres.2020.100919","volume":"83","author":"D Tonade","year":"2021","unstructured":"Tonade D, Kern TS. Photoreceptor cells and RPE contribute to the development of diabetic retinopathy. Prog Retin Eye Res. 2021;83:100919.","journal-title":"Prog Retin Eye Res"},{"key":"5030_CR28","doi-asserted-by":"crossref","unstructured":"Gomulka K, Ruta M. The role of inflammation and therapeutic concepts in diabetic retinopathy-a short review. Int J Mol Sci. 2023;24(2).","DOI":"10.3390\/ijms24021024"},{"key":"5030_CR29","doi-asserted-by":"publisher","first-page":"613051","DOI":"10.3389\/fimmu.2021.613051","volume":"12","author":"E Midena","year":"2021","unstructured":"Midena E, Torresin T, Velotta E, Pilotto E, Parrozzani R, Frizziero L. OCT Hyperreflective Retinal Foci in Diabetic Retinopathy: A Semi-Automatic Detection Comparative Study. Front Immunol. 2021;12:613051.","journal-title":"Front Immunol"},{"key":"5030_CR30","doi-asserted-by":"publisher","first-page":"110064","DOI":"10.1016\/j.exer.2024.110064","volume":"248","author":"E Pilotto","year":"2024","unstructured":"Pilotto E, Parolini F, Midena G, Cosmo E, Midena E. Small Hyperreflective Retinal Foci as in vivo imaging feature of resident microglia activation in geographic atrophy. Exp Eye Res. 2024;248:110064.","journal-title":"Exp Eye Res"},{"issue":"5","key":"5030_CR31","doi-asserted-by":"publisher","first-page":"976","DOI":"10.4103\/1673-5374.355743","volume":"18","author":"L Tang","year":"2023","unstructured":"Tang L, Xu GT, Zhang JF. Inflammation in diabetic retinopathy: possible roles in pathogenesis and potential implications for therapy. Neural Regen Res. 2023;18(5):976\u201382.","journal-title":"Neural Regen Res"}],"container-title":["BMC Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12886-026-05030-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12886-026-05030-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12886-026-05030-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T23:36:24Z","timestamp":1789083384000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12886-026-05030-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,25]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["5030"],"URL":"https:\/\/doi.org\/10.1186\/s12886-026-05030-1","relation":{},"ISSN":["1471-2415"],"issn-type":[{"value":"1471-2415","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,25]]},"assertion":[{"value":"28 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study protocol was approved by The Ethics Committee of Affiliated Hospital of Yunnan University. All procedures performed in studies involving human participants were in accordance with the 1964 Helsinki Declaration and later versions. In addition, for investigations involving human subjects, informed consent has been obtained from the participants involved.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"561"}}